S&P 500   4,590.49 (+0.50%)
DOW   36,204.30 (+0.70%)
QQQ   389.69 (+0.22%)
AAPL   191.22 (+0.67%)
MSFT   374.42 (-1.18%)
META   324.85 (-0.70%)
GOOGL   131.65 (-0.66%)
AMZN   146.85 (+0.52%)
TSLA   237.84 (-0.93%)
NVDA   468.19 (+0.10%)
NIO   7.19 (-1.10%)
BABA   73.69 (-1.59%)
AMD   121.15 (+-0.01%)
T   16.65 (+0.48%)
F   10.53 (+2.63%)
MU   75.82 (-0.39%)
CGC   0.62 (+10.91%)
GE   122.86 (+0.87%)
DIS   92.32 (-0.40%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.57 (+3.40%)
XOM   102.65 (-0.09%)
S&P 500   4,590.49 (+0.50%)
DOW   36,204.30 (+0.70%)
QQQ   389.69 (+0.22%)
AAPL   191.22 (+0.67%)
MSFT   374.42 (-1.18%)
META   324.85 (-0.70%)
GOOGL   131.65 (-0.66%)
AMZN   146.85 (+0.52%)
TSLA   237.84 (-0.93%)
NVDA   468.19 (+0.10%)
NIO   7.19 (-1.10%)
BABA   73.69 (-1.59%)
AMD   121.15 (+-0.01%)
T   16.65 (+0.48%)
F   10.53 (+2.63%)
MU   75.82 (-0.39%)
CGC   0.62 (+10.91%)
GE   122.86 (+0.87%)
DIS   92.32 (-0.40%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.57 (+3.40%)
XOM   102.65 (-0.09%)
S&P 500   4,590.49 (+0.50%)
DOW   36,204.30 (+0.70%)
QQQ   389.69 (+0.22%)
AAPL   191.22 (+0.67%)
MSFT   374.42 (-1.18%)
META   324.85 (-0.70%)
GOOGL   131.65 (-0.66%)
AMZN   146.85 (+0.52%)
TSLA   237.84 (-0.93%)
NVDA   468.19 (+0.10%)
NIO   7.19 (-1.10%)
BABA   73.69 (-1.59%)
AMD   121.15 (+-0.01%)
T   16.65 (+0.48%)
F   10.53 (+2.63%)
MU   75.82 (-0.39%)
CGC   0.62 (+10.91%)
GE   122.86 (+0.87%)
DIS   92.32 (-0.40%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.57 (+3.40%)
XOM   102.65 (-0.09%)
S&P 500   4,590.49 (+0.50%)
DOW   36,204.30 (+0.70%)
QQQ   389.69 (+0.22%)
AAPL   191.22 (+0.67%)
MSFT   374.42 (-1.18%)
META   324.85 (-0.70%)
GOOGL   131.65 (-0.66%)
AMZN   146.85 (+0.52%)
TSLA   237.84 (-0.93%)
NVDA   468.19 (+0.10%)
NIO   7.19 (-1.10%)
BABA   73.69 (-1.59%)
AMD   121.15 (+-0.01%)
T   16.65 (+0.48%)
F   10.53 (+2.63%)
MU   75.82 (-0.39%)
CGC   0.62 (+10.91%)
GE   122.86 (+0.87%)
DIS   92.32 (-0.40%)
AMC   6.86 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.57 (+3.40%)
XOM   102.65 (-0.09%)

Syros Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SYRS)

$2.65
-0.10 (-3.64%)
(As of 02:30 PM ET)
Compare
Today's Range
$2.52
$2.85
50-Day Range
$2.13
$4.00
52-Week Range
$2.09
$5.67
Volume
65,650 shs
Average Volume
86,408 shs
Market Capitalization
$55.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Syros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
363.0% Upside
$12.50 Price Target
Short Interest
Healthy
2.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.78) to ($4.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

151st out of 948 stocks

Pharmaceutical Preparations Industry

59th out of 449 stocks


SYRS stock logo

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock Price History

SYRS Stock News Headlines

Piper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Syros Pharmaceuticals Q3 Loss misses estimates
Preview: Syros Pharmaceuticals's Earnings
Syros Pharmaceuticals Inc SYRS
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Syros Pharmaceuticals (SYRS) Gets a Buy from H.C. Wainwright
Q2 2023 Syros Pharmaceuticals Inc Earnings Call
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/05/2021
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$15.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+363.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-94,650,000.00
Pretax Margin
-1,193.45%

Debt

Sales & Book Value

Annual Sales
$14.88 million
Book Value
$1.72 per share

Miscellaneous

Free Float
18,865,000
Market Cap
$56.89 million
Optionable
Optionable
Beta
1.46
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Nancy A. Simonian M.D. (Age 62)
    President, CEO & Director
    Comp: $955.39k
  • Dr. Richard A. Young Ph.D. (Age 69)
    Scientific Founder, Member of Scientific Advisory Board & Director
    Comp: $108.37k
  • Dr. David A. Roth M.D. (Age 60)
    Chief Medical Officer
    Comp: $679.52k
  • Dr. James E. Bradner M.D. (Age 51)
    Founder
  • Dr. Nathanael S. Gray Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Jason Haas (Age 55)
    Chief Financial Officer
    Comp: $457.22k
  • Ms. Karen Hunady M.S.
    Director of Corporate Communications & Investor Relations
  • Mr. Gerald E. Quirk Esq. (Age 55)
    J.D., Chief Legal & Compliance Officer
    Comp: $127.07k
  • Ms. Lisa Roberts
    Vice President of Human Resources
  • Ms. Kristin Stephens (Age 50)
    Chief Development Officer














SYRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Syros Pharmaceuticals' shares. Their SYRS share price targets range from $7.00 to $15.00. On average, they expect the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 363.0% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2023?

Syros Pharmaceuticals' stock was trading at $3.59 at the start of the year. Since then, SYRS shares have decreased by 24.8% and is now trading at $2.70.
View the best growth stocks for 2023 here
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its quarterly earnings results on Friday, November, 5th. The company reported ($4.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.40) by $0.30. The firm earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. During the same period in the previous year, the company posted ($4.30) earnings per share.

When did Syros Pharmaceuticals' stock split?

Syros Pharmaceuticals's stock reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (7.63%), CHI Advisors LLC (6.27%), LPL Financial LLC (0.44%), Assenagon Asset Management S.A. (0.12%), Clarius Group LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Roth, Eric R Olson, Richard A Young and Timothy Tyson.
View institutional ownership trends
.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SYRS) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -